Table 2.
Studies examining PDE5 expression in the prostate
| Publication year/First author |
Species | Detection method |
Expression level |
Expression location |
Source of PDE5 Antibody |
Tension reversion |
Additional notes | |
|---|---|---|---|---|---|---|---|---|
| 1998/Stacey[32] | Human | Northern | ND | ND | NA | ND | ||
| 1999/Kotera[45] | Human | PCR | PDE5A2 > PDE5A1 | ND | NA | ND | ||
| 2000/Lin[33] | Human | PCR | ND | ND | NA | ND | ||
| 2001/Uckert[38] | Human | PCR, cGMP hydrolysis & Organ bath | ND | ND | NA | Zaprinast > Sildenafil (0.1–100µM) | Both drugs reversed <30% tension at 100µM | |
| 2003/Lin[34] | Rat | PCR & Northern | PDE5A2 > PDE5A1 | ND | NA | ND | ||
| 2004/Morelli[35] | Human | qPCR & Western | Among the highest | ND | Dr. Giorgi | ND | Same level as CC | |
| 2005/Zhang[46] | Rat | qPCR & Western | Medium | ND | Dr. Giorgi | ND | Half level as CC | |
| 2006/Uckert[48] | Human | IF | ND | Glandular & subglandular | Dr. Omori | ND | ||
| 2006/Tinel[19] | Rat | qPCR & Organ bath | Among the lowest | ND | NA | Vardenafil > Sildenafil > Tadalafil | ||
| 2010/Fibbi[42] | Human | qPCR & IHC | Medium | Vascular smooth muscle & endothelium | Dr. Giorgi | ND | ||
| 2010/Zenzmaier[49] | Human | IHC | ND | Stroma; not epithelium | Cell Signaling Technology | ND | PDE5 peptide blocked staining | |
| 2011/Morelli[47] | Human | qPCR & IHC | Low | Vascular smooth muscle & endothelium | Dr. Giorgi | ND | One-quarter level as CC | |
| 2011/Muller[36] | Rat | Western | Extremely low | ND | Cell Signaling Technology | ND | ||
| 2012/Zhang[43] | Rat | qPCR, Western, IHC, & Organ bath | Abundant by PCR & Western; scanty by IHC | Fibromuscular stroma | Transduction Laboratories | Zaprinast at 20 nM potentiated SNP effect |
CC: Corpus cavernosum; PCR: Reverse transcription-polymerase chain reaction; qPCR: Quantitative PCR; IF: Immunofluorescence; IHC: Immunohistochemistry; SNP: Sodium nitroprusside; ND: Not determined; NA: Not applicable.